Home Biotechnology Amgen Inc.
A

Amgen Inc.

Profile managed by Bizz Id
United States 1980

Description

Biotechnology company that discovers, develops, manufactures and delivers medicines. It focuses on general medicine, rare disease, inflammation and oncology, with monoclonal antibodies, BiTE molecules, recombinant proteins and biosimilars. It has a presence in approximately 100 countries.

Products

37 products
ABP 206 (nivolumab biosimilar)

Phase 3. Investigational biosimilar to Opdivo (nivolumab); PD-1 binding antibody; oncology.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABP 234 (pembrolizumab biosimilar)

Phase 3. Investigational biosimilar to Keytruda (pembrolizumab); PD-1 binding antibody; oncology.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABP 692 (ocrelizumab biosimilar)

Phase 3. Investigational biosimilar to Ocrevus (ocrelizumab); CD20 binding antibody; inflammation.

Under development

Finished product (FDF)

Verified on 2026-10-21

ABP 938 (aflibercept 8 mg biosimilar)

Phase 3. Investigational biosimilar to Eylea HD (aflibercept); recombinant fusion protein, VEGF inhibitor.

Under development

Finished product (FDF)

Verified on 2026-10-21

Adalimumab

Brand: Amjevita (adalimumab-atto). Biosimilar to Humira. Rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, polyarticular JIA, ankylosing spondylitis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, uveitis.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Adalimumab: see suppliers →

Aflibercept

Brand: Pavblu (aflibercept-ayyh). Biosimilar to Eylea. Neovascular (wet) AMD, macular edema following RVO, diabetic macular edema, diabetic retinopathy.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

AMG 732 (anti-IGF-1R)

Phase 2. Formerly HZN-280. Monoclonal antibody inhibiting IGF-1R; thyroid eye disease.

Under development

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab

Brand: Mvasi (bevacizumab-awwb). Biosimilar to Avastin. Metastatic colorectal cancer, non-squamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, ovarian, fallopian tube or primary peritoneal cancer.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Bevacizumab: see suppliers →

Blinatumomab

Brand: Blincyto. BiTE molecule anti-CD19 x anti-CD3; acute lymphoblastic leukemia. In development: ALL (Phase 3); systemic lupus erythematosus and refractory rheumatoid arthritis (Phase 2).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Blinatumomab: see suppliers →

Darbepoetin alfa

Brand: Aranesp.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Darbepoetin alfa: see suppliers →

Daxdilimab

Phase 2. Monoclonal antibody anti-ILT7; dermatomyositis, anti-synthetase inflammatory myositis and discoid lupus erythematosus.

Under development

Finished product (FDF)

Verified on 2026-10-21

Daxdilimab: see suppliers →

Dazodalibep

Phase 3. Fusion protein binding CD40L; Sjögren's disease.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dazodalibep: see suppliers →

Denosumab (ref. Prolia)

Brand: Prolia.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Denosumab (ref. Xgeva)

Brand: Xgeva.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Denosumab: see suppliers →

Eculizumab

Brand: Bkemv (eculizumab-aeeb). Interchangeable biosimilar to Soliris. PNH, aHUS, generalized myasthenia gravis, NMOSD.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Eculizumab: see suppliers →

Epoetin alfa

Brand: Epogen.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Epoetin alfa: see suppliers →

Erenumab

Brand: Aimovig (erenumab-aooe). Monoclonal antibody inhibiting the CGRP receptor; migraine. In development: pediatric migraine (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Erenumab: see suppliers →

Etanercept

Brand: Enbrel.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Etanercept: see suppliers →

Evolocumab

Brand: Repatha. Monoclonal antibody inhibiting PCSK9; hypercholesterolemia (new indications in Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Evolocumab: see suppliers →

Filgrastim

Brand: Neupogen.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Filgrastim: see suppliers →

Inebilizumab

Brand: Uplizna (inebilizumab-cdon). Monoclonal antibody binding CD19. In development: autoimmune hepatitis (Phase 3); lupus nephritis (Phase 2).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Inebilizumab: see suppliers →

Infliximab

Brand: Avsola (infliximab-axxq). Biosimilar to Remicade. Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Infliximab: see suppliers →

Interferon gamma-1b

Brand: Actimmune.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Maridebart cafraglutide

Phase 3. MariTide (formerly AMG 133). Antibody-peptide conjugate, GLP-1R agonist and GIPR antagonist; obesity, cardiovascular disease, heart failure, obstructive sleep apnea (Phase 3); elevated liver fat and type 2 diabetes (Phase 2).

Under development

Finished product (FDF)

Verified on 2026-10-21

Maridebart cafraglutide: see suppliers →

Panitumumab

Brand: Vectibix.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Panitumumab: see suppliers →

Pegfilgrastim

Brand: Neulasta.

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pegfilgrastim: see suppliers →

Pegloticase

Brand: Krystexxa. PEGylated uricase; uncontrolled gout. In development: subcutaneous administration (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Pegloticase: see suppliers →

Rituximab

Brand: Riabni (rituximab-arrx). Biosimilar to Rituxan. Non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, GPA and MPA, pemphigus vulgaris.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Rituximab: see suppliers →

Romiplostim

Brand: Nplate. Peptibody, thrombopoietin receptor agonist. In development: chemotherapy-induced thrombocytopenia and untreated primary immune thrombocytopenia (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Romiplostim: see suppliers →

Romosozumab

Brand: Evenity (romosozumab-aqqg). Monoclonal antibody inhibiting sclerostin; bone. In development: pediatric osteogenesis imperfecta (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Romosozumab: see suppliers →

Sunakiment

Phase 2. Formerly AMG 104. Human anti-TSLP Fab; asthma. With AstraZeneca.

Under development

Finished product (FDF)

Verified on 2026-10-21

Sunakiment: see suppliers →

Tarlatamab

Brand: Imdelltra (tarlatamab-dlle). BiTE molecule anti-DLL3 x anti-CD3; small cell lung cancer (in development, Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Tarlatamab: see suppliers →

Teprotumumab

Brand: Tepezza (teprotumumab-trbw). Monoclonal antibody inhibiting IGF-1R; thyroid eye disease. In development: subcutaneous administration (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Teprotumumab: see suppliers →

Tezepelumab

Brand: Tezspire (tezepelumab-ekko). Monoclonal antibody inhibiting TSLP, with AstraZeneca. In development: COPD and eosinophilic esophagitis (Phase 3).

Comercializado (agencia no indicada)

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Tezepelumab: see suppliers →

Trastuzumab

Brand: Kanjinti (trastuzumab-anns). Biosimilar to Herceptin. HER2-overexpressing adjuvant and metastatic breast cancer.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Trastuzumab: see suppliers →

Ustekinumab

Brand: Wezlana (ustekinumab-auub). Interchangeable biosimilar to Stelara. Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis.

Aprobado FDA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ustekinumab: see suppliers →

Xaluritamig

Phase 3. Formerly AMG 509. BiTE molecule targeting STEAP1; prostate cancer (Phase 3), Ewing sarcoma (Phase 1).

Under development

Finished product (FDF)

Verified on 2026-10-21

Xaluritamig: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free